ABILITY received regulatory clearance to begin its first-in-human study of its implantable BCI platform in ALS patients in Europe. The company spun out of the Wyss Center for Bio and Neuroengineering with nearly a decade of institutional development behind it. The clearance marks the first time that technology will be tested directly in patients. ABILITY is targeting speech decoding and motor function restoration as its primary applications.
.svg)
.jpeg)
